GHRP-6 Research Guide — GHS-R1a Ghrelin Receptor Biology, Dual Pituitary/Hypothalamic GH Stimulation & Hormonal Profile (2026)
- GHRP-6 (growth hormone-releasing peptide 6; developmental code SKF-110679; CAS: 87616-84-0; sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂; MW: ~873.02 Da) is a synthetic hexapeptide developed by Cyril Y. Bowers and colleagues at Tulane University, first characterized in 1984 as the founding compound of the growth hormone secretagogue (GHS/GHRP) peptide class. GHRP-6 was the research tool that ultimately led to the identification of the GHS-R1a receptor (Howard et al. 1996) and the discovery of ghrelin as its endogenous ligand (Kojima et al. 1999). YPB offers research-grade GHRP-6 in 10mg (YPB.257) and 5mg (YPB.282) configurations (Research Use Only).
- Mechanism: GHRP-6 activates GHS-R1a (ghrelin receptor; Gq/11-coupled GPCR) at two anatomical sites producing a dual GH-axis response: (1) directly on anterior pituitary somatotrophs (GHS-R1a → Gq/11 → PLC → IP3/DAG → intracellular Ca²⁺ → GH vesicle exocytosis); and (2) indirectly on hypothalamic arcuate nucleus GHS-R1a neurons, stimulating GHRH release and increasing local NPY/AgRP, which amplifies pituitary GH release while also driving the compound’s characteristic potent appetite stimulation.
- Hormonal profile: Non-selective GHS-R1a agonist. Elevates GH in a pulsatile pattern; also co-stimulates cortisol and prolactin at higher doses. Strongest appetite-stimulating effect of all synthetic GHRPs (a potent research compound-2, hexarelin, and ipamorelin) due to robust GHS-R1a activation in hypothalamic appetite circuits. This appetite co-stimulation is the defining pharmacological characteristic distinguishing GHRP-6 from its more selective successors.
- Historical significance: GHRP-6 is the foundational GH secretagogue research tool. Its development preceded the characterization of both its receptor (GHS-R1a, 1996) and the endogenous ligand ghrelin (1999) — making it the research chemical that drove the discovery of an entirely new receptor-ligand system in neuroendocrinology.
- WADA status: Prohibited — Peptide Hormones, Growth Factors, Related Substances and Mimetics (S2), WADA 2025. ~8,100 monthly searches. Updated April 2026.
What Is GHRP-6 and Why Is It the Founding Compound of GH Secretagogue Research?
Founding GHRP (Bowers 1984)
Led to Discovery of Ghrelin (1999)
GHRP-6 (CAS: 87616-84-0; His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂; MW: ~873 Da) is a synthetic hexapeptide that holds a unique position in endocrinology history: it is the founding compound of the growth hormone secretagogue (GHS) peptide class and the research tool that directly led to the identification of both a novel G-protein-coupled receptor and its endogenous ligand — subsequently named ghrelin. Updated April 2026. Cyril Y. Bowers and colleagues at Tulane University discovered in the late 1970s that certain chemical modifications of met-enkephalin peptides produced unexpected growth hormone-releasing activity in pituitary cell cultures that was independent of opioid receptor activation. Through systematic structure-activity relationship studies, Bowers developed GHRP-6, characterized in 1984 as the first synthetic compound to specifically and dose-dependently release GH both in vitro and in vivo through an entirely novel mechanism distinct from growth hormone-releasing hormone (GHRH).
The pharmacological pathway activated by GHRP-6 remained mechanistically unexplained — its receptor was unknown — until Howard et al. (1996) used GHRP-6 and related compounds as pharmacological tools to identify and clone the GHS-R1a (growth hormone secretagogue receptor type 1a). Three years later, Kojima et al. (1999) identified ghrelin as the endogenous ligand for GHS-R1a — establishing that GHRP-6 is a synthetic ghrelin mimetic that activates ghrelin’s receptor, now properly designated the ghrelin receptor. The development of GHRP-6 thus drove the discovery of an entirely new neuroendocrine hormone system.
Key Characteristics
| Parameter | Value |
|---|---|
| Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ (hexapeptide; contains two D-amino acids: D-Trp at position 2 and D-Phe at position 5) |
| CAS Number | 87616-84-0 |
| Molecular Weight | ~873.02 Da |
| Development | Cyril Y. Bowers, Tulane University; first characterized 1984 (Endocrinology); met-enkephalin analog; founding GHRP |
| Receptor | GHS-R1a (ghrelin receptor; growth hormone secretagogue receptor type 1a); Gq/11-coupled GPCR; identified 1996 (Howard et al.) |
| Endogenous Ligand Context | GHRP-6 is a synthetic mimetic of ghrelin (the endogenous GHS-R1a ligand, discovered 1999). GHRP-6 preceded ghrelin discovery by 15+ years. |
| Primary Action Sites | Anterior pituitary somatotrophs (direct GH release) + hypothalamic arcuate nucleus (GHRH stimulation + NPY/AgRP appetite activation) |
| Hormonal Profile | GH (primary) + GHRH (indirect) + cortisol (co-stimulation) + prolactin (co-stimulation at higher doses) |
| Selectivity | Non-selective GHS-R1a agonist; broader hormonal footprint than ipamorelin (which spares cortisol and prolactin) and hexarelin |
| Appetite Effect | Potent orexigenic effect via hypothalamic NPY/AgRP activation — strongest appetite stimulation of all synthetic GHRPs |
| Half-Life | Short (~15–60 minutes in plasma); produces acute pulsatile GH elevations; multiple daily administrations in research protocols |
| FDA Status | Not research-grade. Research Use Only (RUO). |
| WADA Status | Prohibited — Peptide Hormones, Growth Factors, Related Substances and Mimetics (S2), WADA 2025 |
| Storage | Lyophilized: −20°C. Reconstituted: 2–8°C, use within 14 days |
How Does GHRP-6 Work? Dual Pituitary and Hypothalamic GHS-R1a Mechanism
GHRP-6’s GH-releasing mechanism operates at two distinct anatomical levels simultaneously, explaining both its robust GH secretion and its characteristic appetite co-stimulation — effects that are inseparable because they share the same GHS-R1a receptor at different brain locations.
Level 1: Direct Pituitary GH Release
GHS-R1a is expressed on somatotroph cells of the anterior pituitary gland. GHRP-6 binding activates the Gq/11 protein, stimulating phospholipase C (PLC), which cleaves PIP2 to IP3 and DAG. IP3 mobilizes intracellular Ca²⁺ from the endoplasmic reticulum; DAG activates protein kinase C (PKC). This Ca²⁺ surge and PKC activation converge on GH secretory vesicle exocytosis, producing a sharp, pulsatile GH pulse from anterior pituitary somatotrophs. This direct pituitary action is somatostatin-suppressible: concurrent somatostatin (SRIF) infusion blunts GHRP-6-induced GH release, confirming that pituitary somatotroph responsiveness to GHRP-6 is modulated by the same somatostatin brake that governs normal pulsatile GH secretion.
Level 2: Hypothalamic Amplification
GHS-R1a is also expressed on neurons in the hypothalamic arcuate nucleus. GHRP-6 activates these hypothalamic GHS-R1a neurons through two converging effects: (1) it stimulates GHRH release from GHRH neurons, adding an indirect amplification of pituitary GH release on top of the direct pituitary effect (Bowers et al. 1991 confirmed this dual mechanism in rodent models); (2) it activates NPY (neuropeptide Y) and AgRP (agouti-related peptide) neurons in the arcuate nucleus, which are the primary hypothalamic appetite-activating neurons. This NPY/AgRP activation is the direct molecular basis for GHRP-6’s potent appetite stimulation — the defining pharmacological characteristic that distinguishes GHRP-6 from more selective successors like ipamorelin.
Cortisol and Prolactin Co-Stimulation
Unlike ipamorelin (which was specifically engineered to spare cortisol and prolactin), GHRP-6 is a non-selective GHS-R1a agonist. Its robust receptor activation produces modest co-elevation of cortisol (via hypothalamic-pituitary-adrenal axis) and prolactin (via anterior pituitary lactotrophs), particularly at higher used doses. In published research protocols, these cortisol and prolactin co-effects are well-documented and represent an important experimental variable when designing GH axis research studies that require hormonal specificity.
What Research Applications Has GHRP-6 Been Studied For?
GHS-R1a Receptor Pharmacology
GHRP-6 is the historically foundational GHS-R1a pharmacological probe. Published research using GHRP-6 drove the receptor cloning (Howard et al. 1996) and established the GHS-R1a pharmacology that defined the entire GH secretagogue compound class. For researchers studying ghrelin receptor biology, GHRP-6 remains a well-characterized reference agonist with a robust published literature for receptor binding, selectivity, and downstream signaling comparisons.
GH Pulsatility and Somatotroph Biology
GHRP-6’s documented ability to produce pulsatile GH release through Gq/11/PLC/Ca²⁺ signaling makes it a tool for studying somatotroph physiology, GH vesicle exocytosis mechanisms, and the interaction between somatostatin and GHRP at the pituitary level. Bowers et al. (1991) established the dual pituitary/hypothalamic mechanism in detail; the compound has been used in dozens of subsequent mechanistic GH axis studies as a positive control and reference agonist.
Appetite and Energy Homeostasis Research
GHRP-6’s potent NPY/AgRP activation in the hypothalamic arcuate nucleus makes it one of the most effective pharmacological tools available for studying appetite circuit activation. Published research documents the downstream NPY/AgRP signaling cascade, the relationship between arcuate GHS-R1a activation and meal-initiation behavior, and the ghrelin receptor’s role in hedonic vs. homeostatic feeding. The appetite effect is GHS-R1a-specific and is distinct from hypoglycemia-driven hunger, allowing researchers to dissect ghrelin receptor-dependent orexigenic signaling from metabolic state-dependent hunger.
Clinical Wasting and Cachexia Research
GHRP-6’s combination of GH stimulation and potent appetite activation has been studied in clinical wasting conditions where both anabolic and orexigenic effects are desired simultaneously. Published data from early clinical investigations examined GHRP-6 IV and SC administration in humans, documenting dose-dependent GH elevation at 1–2 mcg/kg IV with well-characterized kinetics.
What Does the Human and Preclinical Research Data Show?
| Study / Context | Route / Design | Key Finding & Adverse Events | Year |
|---|---|---|---|
| Bowers et al. — Original characterization | In vitro + in vivo rodent models | GHRP-6 dose-dependently releases GH from pituitary cells in vitro and in vivo; mechanism independent of GHRH and opioid receptors confirmed. Foundational characterization of GHS class. (Endocrinology, 1984; Endocrinology, 1991) | 1984, 1991 |
| Howard et al. — GHS-R1a receptor cloning | Molecular biology (receptor expression cloning using GHRP-6) | GHS-R1a receptor identified and cloned using GHRP-6 as the pharmacological probe for activity-based receptor expression screening. Receptor characterized as Gq/11 GPCR. Paved way for ghrelin discovery 1999. (Science, 1996) | 1996 |
| Bowers et al. — Human GH data | IV / healthy human volunteers | GHRP-6 at 1–2 mcg/kg IV produced dose-dependent GH elevation in healthy humans; peak GH response within 15–30 minutes; cortisol and prolactin co-elevation documented at higher doses. Well tolerated at doses studied. Appetite stimulation noted by participants within 20–30 minutes post-administration. | 1990s |
| Combo with GHRH | IV / human subjects | Combined GHRP-6 + GHRH produces supra-additive GH release vs. either alone, confirming dual mechanism (pituitary direct + hypothalamic GHRH stimulation) and the synergy of combined pituitary/hypothalamic stimulation. Published across multiple human studies. | Various |
How Does GHRP-6 Compare to Other GH Secretagogue Research Peptides?
| Parameter | GHRP-6 | Ipamorelin | Hexarelin | Sermorelin |
|---|---|---|---|---|
| Receptor | GHS-R1a (ghrelin receptor); Gq/11 | GHS-R1a (ghrelin receptor); Gq/11 — more selective agonism | GHS-R1a (primary) + CD36 (cardiac); dual mechanism | GHRHR (GH-releasing hormone receptor); Gs/adenylate cyclase/cAMP |
| GHS-R1a Selectivity | Non-selective: co-stimulates cortisol + prolactin | Highly selective: spares cortisol and prolactin | Non-selective: co-stimulates cortisol + prolactin; tachyphylaxis documented | Not GHS-R1a (GHRH analog — different receptor entirely) |
| Appetite Stimulation | Strongest of all synthetic GHRPs (potent NPY/AgRP arcuate nucleus activation) | Minimal appetite stimulation | Moderate appetite stimulation | None (GHRH receptor; no appetite circuit overlap) |
| Cortisol Elevation | Yes — documented at higher doses; important experimental variable | No — key selectivity advantage over GHRP-6 | Yes — more pronounced than GHRP-6 at equivalent doses | No (GHRH mechanism; no cortisol co-effect) |
| Historical Significance | Founding GHRP (1984); led to GHS-R1a discovery (1996) and ghrelin discovery (1999) | Derived from GHRP-6 class; engineered for selectivity | Most potent GHRP for raw GH output; dual GHS-R1a + CD36 | GHRH analog; different receptor class entirely from GHRPs |
| Tachyphylaxis | Mild receptor downregulation with chronic use (less than hexarelin) | Minimal tachyphylaxis (key advantage) | Pronounced tachyphylaxis documented | Minimal (GHRH analog; different receptor) |
| YPB SKU | YPB.257 (10mg) / YPB.282 (5mg) | YPB.263 — see guide | YPB.261 — see guide | YPB.211 — see guide |
GHRP-6, ipamorelin, and hexarelin all share GHS-R1a as their primary receptor but differ critically in selectivity. GHRP-6 is the foundational reference compound with the broadest hormonal footprint (GH + cortisol + prolactin + appetite); ipamorelin (see the Ipamorelin Research Guide) is the selective successor that spares cortisol and prolactin; hexarelin (see the Hexarelin Research Guide) is the most potent GHRP but adds CD36 cardiac effects. Sermorelin (see the Sermorelin Research Guide) uses a completely different receptor (GHRHR) and is synergistic when combined with GHRPs.
What Should Researchers Know About GHRP-6 Stability and Handling?
D-Amino Acid Stability Advantage
GHRP-6’s two D-amino acid substitutions (D-Trp at position 2, D-Phe at position 5) provide meaningful resistance to proteolytic degradation compared to all-L-amino acid peptides of equivalent length. Standard serine and cysteine protease cleavage is significantly attenuated at D-amino acid sites. However, some plasma peptidases do cleave GHRP-6; in vitro plasma half-life is on the order of 15–60 minutes. For research protocols requiring extended GHS-R1a stimulation, this short half-life necessitates multiple administrations or consideration of slower-acting GHS-R1a agonists.
Storage and Reconstitution
Lyophilized GHRP-6 is stable at −20°C for up to 24 months. Reconstitute with bacteriostatic water; once reconstituted, hold at 2–8°C and use within 14 days. Avoid repeated freeze-thaw cycles. Protect from light; Trp residues are photosensitive (Trp appears twice in the sequence: Trp at position 4, D-Trp at position 2).
COA Verification
HPLC purity (≥98%) and MS confirmation at ~873.02 Da. The two D-amino acid residues cannot be distinguished from L-amino acids by standard molecular weight analysis alone; amino acid analysis and optical rotation testing, or chiral HPLC, are the definitive verification methods for D/L amino acid configuration. At minimum, MS confirmation at 873 Da (not 871 or 875 — which would indicate oxidation of Trp residues) is required. All YPB GHRP-6 batches include lot-traceable COA documentation through the COA Library.
Key Research Findings
- Founding GHRP compound (Bowers 1984): First synthetic compound to dose-dependently release GH via a non-GHRH, non-opioid mechanism; all subsequent GHRPs (GHRP-2, ipamorelin, hexarelin) derive from the GHRP-6 chemical scaffold.
- Drove GHS-R1a receptor discovery (Howard et al. Science 1996): GHRP-6 was the pharmacological probe used to identify and clone GHS-R1a — a receptor whose endogenous ligand was unknown until ghrelin was discovered (Kojima et al. 1999). GHRP-6 is a synthetic ghrelin mimetic discovered 15 years before ghrelin itself.
- Dual pituitary + hypothalamic action: Direct somatotroph GH exocytosis (Gq/11/PLC/Ca²⁺) + indirect GHRH stimulation from hypothalamic arcuate nucleus → supra-additive GH release with exogenous GHRH confirmed in published human studies.
- Strongest appetite stimulation of all GHRPs: NPY/AgRP arcuate nucleus activation drives potent orexigenic response within 20–30 minutes; qualitatively different from hypoglycemia-driven hunger; useful research tool for GHS-R1a appetite circuit studies.
- Non-selective hormonal profile: Cortisol and prolactin co-elevation documented at higher doses — the key experimental variable distinguishing GHRP-6 from selective GHRPs (ipamorelin) in GH axis research requiring hormonal specificity.
- D-amino acid structural innovation: Two D-amino acid substitutions (D-Trp-2, D-Phe-5) confer GHS-R1a agonism and partial peptidase resistance; a pioneering example of D-amino acid use in peptide compound design that became standard practice.
- WADA S2 prohibited: Listed under Peptide Hormones, Growth Factors, Related Substances and Mimetics — reflects recognized GH-elevating activity confirmed in published human research.
- Trp photosensitivity: Two tryptophan residues in the sequence (Trp-4, D-Trp-2) are susceptible to oxidative degradation; protect from light and UV exposure during storage and research handling.
Browse the Full Research Catalog
Market Demand and Research Interest
| Demand Indicator | GHRP-6 Data Point |
|---|---|
| Monthly US searches | ~8,100/mo |
| PubMed publications | 500+ (GHRP-6 / growth hormone releasing hexapeptide) |
| Historical significance | Founding GHRP (1984); led to GHS-R1a receptor identification (1996) and ghrelin discovery (1999) |
| Key publications | Bowers et al. (1984) Endocrinology; Howard et al. (1996) Science (receptor cloning); Kojima et al. (1999) Nature (ghrelin) |
| Unique research position | Foundational GHS-R1a reference agonist; strongest appetite stimulation of all GHRPs; historically irreplaceable research tool |
| Catalog completion role | Completes the full YPB GH secretagogue spectrum: GHRP-6 (founding, non-selective) + Ipamorelin (selective) + Hexarelin (most potent, dual mechanism) + Sermorelin (GHRHR class) |
| Keyword difficulty range | Low-medium (KD <20) |
How Can Researchers Offer GHRP-6 Under Their Own Brand?
GHRP-6 Wholesale Pricing & Margin Analysis
| SKU | Configuration | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.257 (RUO) | GHRP-6 Acetate 10mg | TBC Premier | TBC Core | TBC | TBC at Premier tier |
| YPB.282 (RUO) | GHRP-6 Acetate 5mg | TBC Premier | TBC Core | TBC | TBC at Premier tier |
Contact the YPB team for confirmed Premier and Core tier pricing on both GHRP-6 configurations. Use the YPB Profit Calculator to model projected revenue. White-label brands offering the complete GH secretagogue research catalog — GHRP-6 (founding reference agonist), Ipamorelin (selective), Hexarelin (most potent), and Sermorelin (GHRHR class) — cover the entire GH axis pharmacology research spectrum from a single buyer audience. Download the full catalog for all GH axis SKU pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed searched for “GHRP-6,” “growth hormone releasing hexapeptide,” “growth hormone secretagogue receptor,” “GHS-R1a,” and CAS 87616-84-0. Search conducted through April 2026.
Key sources: Bowers et al. (1984) Endocrinology (original GHRP-6 characterization); Bowers et al. (1991) Endocrinology (dual pituitary/hypothalamic mechanism, PMID: 1987938); Howard et al. (1996) Science 273:974–977 (GHS-R1a receptor cloning using GHRP-6); Kojima et al. (1999) Nature 402:656–660 (ghrelin identification as endogenous GHS-R1a ligand).
Limitations: YPB GHRP-6 (YPB.257/.282) is research-grade material designated Research Use Only. Human GH data comes primarily from early Bowers-group clinical studies; large-scale modern RCT data for GHRP-6 alone is limited compared to more recently developed GHRPs. Cortisol and prolactin co-elevation are documented experimental variables at higher doses. This article is for educational purposes only.
References
- Bowers, C. Y., Momany, F. A., Reynolds, G. A., & Hong, A. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114(5), 1537–1545.
- Bowers, C. Y., Sartor, A. O., Reynolds, G. A., & Badger, T. M. (1991). On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology, 128(4), 2027–2035. PMID: 1987938
- Howard, A. D., Feighner, S. D., Cully, D. F., Arena, J. P., Liberator, P. A., Rosenblum, C. I., Hamelin, M., Hreniuk, D. L., Palyha, O. C., Anderson, J., Paress, P. S., Diaz, C., Chou, M., Liu, K. K., McKee, K. K., Pong, S.-S., Chaung, L.-Y., Elbrecht, A., Dashkevicz, M., … Van der Ploeg, L. H. T. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974–977.
- Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656–660.
- Dickson, S. L., Leng, G., & Robinson, I. C. A. F. (1993). Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons. Neuroscience, 52(2), 303–306.
- Bowers, C. Y. (1998). Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci, 54(12), 1316–1329. PMID: 9893715
- Ghigo, E., Arvat, E., Muccioli, G., & Camanni, F. (1997). Growth hormone-releasing peptides. Eur J Endocrinol, 136(5), 445–460.
- Smith, R. G., Cheng, K., Schoen, W. R., Pong, S. S., Hickey, G., Jacks, T., Butler, B., Chan, W. W., Chaung, L. Y., Judith, F., Taylor, J., Wyvratt, M. J., & Fisher, M. H. (1993). A nonpeptidyl growth hormone secretagogue. Science, 260(5114), 1640–1643.
- Laron, Z. (1995). Growth hormone secretagogues — clinical experience and potential wellness benefit. compounds, 50(4), 595–601.
Frequently Asked Questions
GHRP-6 (CAS: 87616-84-0; His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂; ~873 Da; hexapeptide) is the founding synthetic growth hormone secretagogue, first characterized by Bowers et al. (1984, Endocrinology). In research models, it activates GHS-R1a (ghrelin receptor; Gq/11-coupled GPCR) at two sites: (1) anterior pituitary somatotrophs (Gq/11→PLC→IP3/DAG→Ca²⁺ →GH exocytosis); and (2) hypothalamic arcuate nucleus (GHRH stimulation + NPY/AgRP appetite circuit activation). This dual action produces pulsatile GH elevation accompanied by the strongest appetite stimulation of any synthetic GHRP and modest cortisol/prolactin co-elevation at higher doses. GHRP-6’s development led to GHS-R1a receptor cloning (Howard et al. 1996) and ghrelin discovery (Kojima et al. 1999). WADA S2 prohibited. Research Use Only (RUO). Updated April 2026.
GHRP-6 was characterized in 1984 as a potent GH secretagogue acting through a novel non-GHRH, non-opioid mechanism. The receptor mediating this effect was unknown for over a decade. In 1996, Howard and colleagues used GHRP-6 (along with related synthetic GHS compounds) as pharmacological probes in a receptor expression cloning strategy: they expressed cDNA libraries in Xenopus oocytes and used GHRP-6-stimulated intracellular Ca²⁺ signaling as the functional readout to identify and clone the receptor, naming it GHS-R1a (growth hormone secretagogue receptor type 1a; Science, 1996). At that time, the endogenous ligand for GHS-R1a was still unknown — the receptor was an “orphan.” Three years later, Kojima and colleagues in Japan used GHS-R1a as the target in a reverse pharmacology strategy — searching for endogenous compounds that activate the receptor — and identified ghrelin, an acylated 28-amino acid peptide from the stomach, as the natural GHS-R1a ligand (Nature, 1999). The discovery chain: Bowers’ synthetic GHRP-6 (1984) → Howard’s GHS-R1a receptor (1996) → Kojima’s ghrelin (1999). GHRP-6 is a synthetic ghrelin mimetic that was discovered 15 years before ghrelin itself.
Both GHRP-6 and ipamorelin activate GHS-R1a, but with different selectivity profiles at different receptor-expressing cell populations. GHRP-6’s robust GHS-R1a activation in the hypothalamic arcuate nucleus strongly engages NPY (neuropeptide Y) and AgRP (agouti-related peptide) neurons — the primary hypothalamic appetite-activating neurons — producing intense orexigenic signaling within 20–30 minutes. This is the same pathway through which ghrelin (the endogenous GHS-R1a ligand) drives hunger; GHRP-6 mimics ghrelin’s appetite-activating effects because it activates ghrelin’s receptor. Ipamorelin was specifically engineered to have a narrower pharmacological selectivity profile at GHS-R1a that produces robust pituitary GH release while minimizing the hypothalamic NPY/AgRP appetite circuit activation — hence the much weaker appetite stimulation. The cortisol and prolactin co-effects of GHRP-6 (also absent with ipamorelin) reflect similar differences in receptor population selectivity at pituitary lactotrophs and HPA axis neurons. GHRP-6’s broader hormonal footprint is precisely what makes it the foundational research tool for GHS-R1a biology studies where all receptor-mediated effects need to be characterized.
GHRP-6 contains two D-amino acid substitutions: D-Trp at position 2 and D-Phe at position 5. These are non-natural amino acid configurations (the mirror image of the standard L-amino acids found in natural proteins). Their presence serves two functions. First, they are required for GHS-R1a agonist activity: when Bowers and colleagues replaced these D-amino acids with their L-counterparts in structure-activity relationship studies, GH-releasing activity was substantially reduced or abolished, demonstrating that the D-amino acid configuration is a required pharmacophore element for receptor engagement. Second, D-amino acids resist cleavage by most standard proteases (chymotrypsin, trypsin, aminopeptidases), providing partial metabolic stability vs. all-L-amino acid peptides of equivalent length. This was a pioneering application of D-amino acid substitution as a peptide compound design strategy. For COA verification, standard MS cannot distinguish D- from L-amino acid configuration; chiral HPLC or optical rotation testing is required for definitive D/L confirmation beyond MW verification.
The choice depends on what the research protocol requires. GHRP-6 is the appropriate choice when: (1) the study requires characterization of the full GHS-R1a pharmacological profile including appetite, cortisol, and prolactin co-effects (GHRP-6 activates all GHS-R1a-mediated pathways, making it the reference agonist for comprehensive receptor biology studies); (2) the research specifically studies ghrelin receptor biology and requires a compound with extensive published literature for mechanistic comparisons; or (3) the protocol studies combined appetite/GH effects simultaneously. Ipamorelin is the appropriate choice when: (1) isolated GH axis research requires selective GH elevation without cortisol or prolactin co-stimulation as confounding variables; (2) the protocol requires repeat-dose administration where cortisol co-elevation would complicate interpretation; or (3) the research focuses on GH pulsatility without appetite or HPA axis involvement. In general, GHRP-6 is preferred for fundamental GHS-R1a pharmacology research; ipamorelin is preferred for clean, selective GH axis interventions. Both are available in the YPB catalog.
Yes. YourPeptideBrand.com provides white-label dropship for GHRP-6 in 5mg (YPB.282) and 10mg (YPB.257) configurations (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with GHS-R1a mechanism descriptions, historical context (Bowers 1984 founding characterization), and COA library links. Contact the YPB team for confirmed Premier and Core pricing, and use the profit calculator to model projected revenue.
Every GHRP-6 batch includes a lot-specific COA: HPLC purity (≥98%), MS confirmation at ~873.02 Da, endotoxin (<1 EU/mg), TAMC, and TYMC. Trp oxidation check is recommended given the two tryptophan residues in the sequence (Trp-4, D-Trp-2); oxidized Trp would appear at 889 Da (MW + 16 per Trp oxidation) — any batch showing significant 889 Da peak alongside the 873 Da peak should be rejected. For research applications requiring D-amino acid configuration verification, request chiral amino acid analysis beyond standard MS/HPLC. All lots are traceable through the batch-specific COA library.
GHRP-6 and ipamorelin share the same primary receptor (GHS-R1a) but differ meaningfully in selectivity and research applications — making them complementary, not duplicative, in a research catalog. Position GHRP-6 as the foundational reference agonist: the historically significant compound that defined the GHRP class, activates the full GHS-R1a pharmacological spectrum (GH + cortisol + prolactin + appetite), and serves as the standard reference agonist for GHS-R1a biology research. Position ipamorelin as the selective next-generation GHS-R1a agonist: engineered for clean GH elevation without cortisol, prolactin, or appetite co-stimulation, ideal for GH axis research protocols requiring hormonal specificity. The two products cover distinct research protocol requirements from the same GH axis buyer audience and cross-sell naturally: researchers using ipamorelin for selective GH protocols will want GHRP-6 for comparative GHS-R1a selectivity studies and vice versa.
Key Takeaways
Research Takeaways
- Founding GHRP (Bowers 1984): First synthetic GH secretagogue; founding compound from which all GHRPs (GHRP-2, ipamorelin, hexarelin) descended; drove GHS-R1a receptor discovery (Howard 1996) and ghrelin discovery (Kojima 1999).
- Dual pituitary + hypothalamic mechanism (PMID: 1987938): Direct somatotroph GH exocytosis (Gq/11/PLC/Ca²⁺) + hypothalamic GHRH stimulation; supra-additive GH with exogenous GHRH confirmed in published human data.
- Strongest GHRP appetite stimulation: Arcuate nucleus NPY/AgRP activation drives potent orexigenic response (20–30 min post-administration); GHS-R1a-specific; distinct from hypoglycemia-driven hunger; key GHS-R1a appetite circuit research tool.
- Non-selective hormonal profile: Cortisol + prolactin co-elevation documented — important experimental variable; distinguishes GHRP-6 from selective successors (ipamorelin) in GH research requiring specificity.
- D-amino acid pharmacophore (D-Trp-2, D-Phe-5): Required for GHS-R1a agonism; provides partial peptidase resistance; cannot be confirmed by MS alone — chiral HPLC required for D/L verification.
- Trp photosensitivity: Two Trp residues (positions 2 and 4) — oxidized Trp appears at MW+16 in MS; protect from light and confirm absence of 889 Da peak in COA.
Business Takeaways
- ~8,100 monthly searches — established GH axis research audience; completes the GHRP catalog alongside Ipamorelin, Hexarelin, and Sermorelin.
- Two SKU configurations (5mg/10mg) — natural upsell within the compound; contact YPB for confirmed wholesale pricing.
- Completes the GH axis research catalog: GHRP-6 (founding/non-selective) + Ipamorelin (selective) + Hexarelin (most potent/dual) + Sermorelin (GHRHR class) = comprehensive GH axis pharmacology coverage from a single buyer audience.
- Historical narrative advantage — “the compound that led to the discovery of ghrelin” is a compelling content story that no competitor communicates effectively.
Ready to add GHRP-6 to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”ghrp-6″]